TRACON Pharmaceuticals Inc. (OTCQB:TCON) Q4 2019 Earnings Conference Call February 27, 2020 4:30 PM ET
Company Participants
Charles Theuer - President and CEO
Scott Brown - Chief Accounting Officer
Conference Call Participants
Swapnil Malekar - Jefferies
Bert Hazlett - BTIG
Operator
Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Fourth Quarter and Year-End 2019 Earnings Conference Call. At this time, all callers are in a listen-only mode. After the speaker's prepared remarks, we will conduct a question-and-answer session, and instructions will be given at that time.
During today's call, we'll be making certain forward-looking statements, including statements regarding expected timing of clinical trials and results, regulatory activities, future expenses and cash runway, and our development plans and strategy. These statements are subject to various risks that are described in our filings made with the Securities and Exchange Commission, including our Annual Report on Form 10-K, for the year-ended December 31, 2018, and subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements.
Now, I would like to turn the call over to Dr. Charles Theuer, President and CEO of TRACON Pharmaceuticals. Dr. Theuer?
Charles Theuer
Good afternoon, and thank you for joining TRACON's fourth quarter and full-year 2019 financial results and business update conference call. I will begin with an update on our pipeline and recent activities. Following that, our Chief Accounting Officer, Scott Brown, will review our financial results for the three months and year-ended December 31, 2019. Finally, we will conclude by taking your questions.
Our primary efforts are currently focused on our recently in-licensed product candidate Envafolimab, a late-stage potential best-in-class, PDL-1 checkpoint inhibitor by virtue of its subcutaneous route of administration. We expect to begin enrollment in a potential
- Read more current TCON analysis and news
- View all earnings call transcripts